Addex director reprices 1.37M shares, 273K options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Addex Therapeutics Ltd. (ADXN) reported that director Raymond George Hill had paired administrative transactions on September 2, 2026 to reflect repricing of previously granted equity awards. A total of 1,365,532 shares of common stock and options over 273,107 shares were recorded as dispositions to the issuer and simultaneous grants at a reduced exercise price of $0.032 per share, while all other terms of the plans and options remained unchanged. No Rule 10b5-1 trading plan is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock-option (Right to Buy) F3, F2 | 273,107 | $0.00 | $0.00 |
| Grant/Award | Stock-option (Right to Buy) F3, F2 | 273,107 | $0.00 | $0.00 |
| Disposition | Common Stock F1 | 1,365,532 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1 | 1,365,532 | $0.00 | $0.00 |
Footnotes (3)
- F1. Represents 1,365,532 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 797,563 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 567,969 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.
- F2. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.
- F3. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.
Key Figures
Key Terms
deferred strike price payment plan financial
Remuneration Committee financial
Rule 16b-6(d) regulatory
Rule 16b-3 regulatory
exchange act regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did ADXN director Raymond George Hill report on September 2, 2026?
What exercise price change was disclosed for ADXN equity awards on September 2, 2026?
Were Raymond George Hill’s ADXN transactions made under a Rule 10b5-1 trading plan?
How were currency conversions handled in the ADXN option repricing for Raymond George Hill?
AI-generated analysis. How Rhea-AI works. Not financial advice.